Flagship explainer
What drives Lineage Cell Therapeutics, Inc.’s return on equity?
ROE is five filed business factors multiplied together.
| Input | Value | Fiscal year | Source |
|---|---|---|---|
| −$63.5M | FY2025 |
| |
| Income before tax | −$68.6M | FY2025 |
|
| Operating income | −$36.6M | FY2025 |
|
| $14.6M | FY2025 |
| |
| Ending assets | $113M | FY2025 |
|
| Beginning assets | $113M | FY2024 |
|
| $44.5M | FY2025 |
| |
| $78.4M | FY2024 |
|
Source:
- SEC filingFiling detailsAccession 0000950170-25-036309
- SEC filingFiling detailsAccession 0001193125-26-093992